Be a Smart Investor
Tuesday, September 6, 2016
D-Day For KPTI Today
Karyopharm Therapeutics Inc. is slated to provide an overview of top-line results from its phase 2b study of oral Selinexor in multiple myeloma, dubbed STORM, today.
from RTT - Biotech http://ift.tt/2bPHGnb
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment